Ensacove is FDA-approved to treat non-small-cell lung cancer (NSCLC) in adults whose cancer meets all of the following requirements: ALK-positive, which means the cancer has certain abnormal ...

This mutation boosts your odds of several types of cancers, including lung cancer. ALK-positive lung cancer is usually adenocarcinoma, which means that it starts in the mucous glands of your lungs.

The original and still most widely-used test for ALK-positive lung cancer was co-developed by Leila Garcia, PhD, director of the Cytogenetics Core Resource at the University of Colorado Cancer Center.

The study is the first, to the researchers’ knowledge, to evaluate both survival and cost metrics across non-small cell lung ...

Roche's Alecensa has been recommended for routine NHS use as an adjuvant treatment for ALK-positive non-small cell lung cancer (NSCLC), the first targeted therapy for this indication. Alecensa ...

Lung cancer is the leading cause of cancer death worldwide, with various subtypes affecting millions of people each year. Among these, ALK-positive lung cancer frequently strikes younger people ...

The FDA approved ensartinib (Ensacove) as a first-line treatment for adults with ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC), the agency announced on Wednesday.

In 5-year follow-up data from the phase III CROWN trial of ALK-positive advanced non-small cell lung cancer (NSCLC), patients receiving lorlatinib (Lorbrena) had the longest progression-free ...

"We are excited to collaborate with the University of Michigan Rogel Cancer Center and ALK Positive, a group that is dedicated to helping patients with this specific subset of lung cancer ...